Book a Meeting

ADCC-Enhanced Anti-Human B7-H3 (Omburtamab) Antibody (CAT#: BioBet-CB-086LX) Datasheet

Target
B7-H3
Isotype
IgG1
Description
ADCC-Enhanced Anti-Human B7-H3 (Omburtamab) Antibody is a glycosylation-modified anti- therapeutic antibody.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced B7-H3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD276
Full Name
CD276 molecule
Background
The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. Additionally, it was observed that the 3' UTR of this transcript contains a target site for miR29 microRNA, and there is an inverse correlation between the expression of this protein and miR29 levels, suggesting regulation of expression of this gene product by miR29. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
Alternative Names
4Ig-B7-H3; B7-H3; B7H3; B7RP-2
Gene ID
80381
UniProt ID
Q5ZPR3
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Omburtamab
Host
Murine
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human B7-H3 (Omburtamab) Antibody is derived from clone Omburtamab, which is a Murine monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the B7-H3, and it is intended for the research of Neuroblastoma central nervous system/leptomeningeal metastases .
Indication
Neuroblastoma central nervous system/leptomeningeal metastases

Similar to the parental antibody Omburtamab, ADCC-Enhanced Anti-Human B7-H3 (Omburtamab) Antibody targets to the antigen B7-H3, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.

Related Products

Non-Fucosylated Anti-Human B7-H3 (Omburtamab) Therapeutic Antibody (CAT#: BioBet-1824ZP)
Non-Fucosylated Anti-Human B7-H3 (MGA271) Therapeutic Antibody (CAT#: BioBet-654ZP)
Non-Fucosylated Anti-Human B7-H3 (DS-5573a) Therapeutic Antibody (CAT#: BioBet-1791ZP)
ADCC-Enhanced Anti-Human B7-H3 (131I-omburtamab) Antibody (CAT#: BioBet-CB-057LX)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany